Tag archive for ‘Target price’

Teva Pharmaceutical Upgraded to ‘Outperform’ by Oppenheimer

Deutsche Bank set a $68.00 target price on Teva Pharmaceutical Industries (NASDAQ:TEVA) in a research note released on Monday morning. The firm currently has a a buy rating on the stock. Deutsche Bank has also More...

Wordpress site Developed by Fixing WordPress Problems